Hans Ehrencrona
21 – 30 of 81
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2019
-
Mark
Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study
(
- Contribution to journal › Article
-
Mark
Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants : An ENIGMA resource to support clinical variant classification
(
- Contribution to journal › Article
- 2018
-
Mark
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI) : a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
(
- Contribution to journal › Article
-
Mark
Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations
(
- Contribution to journal › Article
-
Mark
The BRCA1 c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant : Breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium
(
- Contribution to journal › Article
-
Mark
Individuals with FANCM biallelic mutations do not develop Fanconi anemia, but show risk for breast cancer, chemotherapy toxicity and may display chromosome fragility
(
- Contribution to journal › Article
-
Mark
Use of the BOADICEA Web Application in clinical practice : appraisals by clinicians from various countries
(
- Contribution to journal › Article
- 2017
-
Mark
Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia
(
- Contribution to journal › Article
-
Mark
Evaluation of polygenic risk scores for breast and ovarian cancer risk prediction in BRCA1 and BRCA2 mutation carriers
(
- Contribution to journal › Article
-
Mark
Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer
(
- Contribution to journal › Article